Transcription

1 3 RD CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND CO-INFECTION WITH HIV LJUBLJANA, SLOVENIA SEPTEMBER 2017 EVALUATION REPORT

2 EXECUTIVE SUMMARY The 3 rd edition of the CENTRAL EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND CO-INFECTION WITH HIV took place on September 2017 at the Grand Hotel Union in Ljubljana, Slovenia. With over 220 participants from 33 countries, it was a huge success. This high profile conference brought together stakeholders from the Central and Eastern European countries to share research results, important clinical developments and updates on ongoing and new trials in the field of Viral hepatitis and co-infection with HIV. The program featured invited lectures, a round table discussion, symposia, oral abstract presentations and poster viewing sessions; thus providing a unique opportunity to meet colleagues in a scientific focused setting. Special attention was given to the empowerment of early career investigators in this region who received a free registration upon acceptance of their abstract and could apply for a travel grant. INTENT TO CHANGE The conference was very well received, which is reflected by the evaluation results. 97% of the respondents indicated that the lectures given in this conference have increased their knowledge, 95% agreed that the program is beneficial for the clinical management of their patients, 98% reported that they intend to incorporate the new information into the care of their patients. PROGRAM The program included 10 invited lectures, 1 round table discussion, 1 clinical case presentation, 8 oral abstract presentations, regular poster viewing sessions and company-sponsored symposia. As in the previous editions, the very well received first session was dedicated to brief (10 min) country - specific presentations. Ample time was allocated for discussion. The program was CME - accredited by UEMS - EACCME. The evaluation scores of the presentations can be found on pages ABSTRACTS The Organizing Committee received 41 abstract. Out of them, among them 8 were accepted for the oral presentations and 29 for the poster presentations. The respondents confirmed that the scientific content of the abstracts was (highly) relevant to their work (80%) and that the topics were (very) interesting (84%). FUTURE The needs assessment, conducted on Day 1 (p. 9) shows that 95% of the participants feel the need programs on viral hepatitis and co-infection with HIV, focused on regional challenges and building collaborations. The majority of the respondents very much appreciated the conference to such an extent that they would recommend the meeting to their colleagues (97%) and plan to attend the meeting in 2018 (85%). Preparations are underway for the 4 th edition, which will take place in Fall 2018 in Prague, Czech Republic. 2

3 TABLE OF CONTENTS Executive summary... 2 Meeting description... 4 Meeting demographics... 5 Committees... 7 Needs assessment... 9 Participants feedback Invited lectures...10 Poster viewing session...14 Industry - sponsored symposia...15 Meeting objectives...17 Learning objectives...17 Conference organization...17 General conference experience...18 Intent to change...18 Meeting metrics Conclusion Acknowledgements

4 MEETING DESCRIPTION BACKGROUND The Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV was initiated in 2014 and has been developed by regional and international Key Opinion Leaders for the medical and scientific community in Eastern and Central European countries. Advances in the treatment of viral Hepatitis and HIV are continuing at a rapid and exciting pace, presented and discussed at many large international conferences. Key challenges in the treatment of Hepatitis B and C as well as HIV are specific for this region and need to be discussed among clinicians and scientists from these countries. This meeting aims to provide a unique and much needed platform for scientific and medical interchange and education on treatment of Viral Hepatitis and Co-infection with HIV. The main objective of this meeting is to guide the Central/ Eastern healthcare community regarding best practice for treating viral hepatitis and HIV co-infection and for stimulating collaborations to reach optimal patient care in this region. MEETING OBJECTIVES To educate the practicing clinician on the best treatment options for Viral Hepatitis & Co-infection with HIV; To share cutting-edge information and translate to daily clinical practice; To provide a Central/Eastern-European platform for interaction and dialogue; To stimulate discussion among different disciplines; To build collaborations and develop research activities. FORMAT This 2 - day international meeting consists of invited lectures, round-table discussions, symposia, oral abstract- and poster presentations. In order to ascertain an interactive workshop setting, much time is allocated to discussion. As the meeting is abstract driven, it is an excellent platform for young investigators to present their research. To ensure the quality of the accepted abstracts, all submitted abstracts go through a blind, peer-reviewed process conducted by the members of the Organizing and Scientific Committees. UNIQUE MEETING FEATURES This independent program is developed by regional and international Key Opinion Leaders for the medical and scientific community in Eastern and Central European countries This meeting aims to provide a unique and much needed platform for scientific and medical interchange and education on treatment of Viral Hepatitis and Coinfection with HIV It is a focused meeting to address regional challenges and to build collaborations in order to advance the field TARGET AUDIENCE The target audience of this meeting consists of healthcare professionals involved in daily care for patients such as infectious disease doctors, gastro-enterologists, hepatologists and others. LEARNING OBJECTIVES After participating in this activity, the participants will: Have an understanding of the basic concepts of Viral Hepatitis and Co-infection; Have an insight into the spread of Viral Hepatitis in Central/Eastern Europe; Be updated on the latest developments in treatment strategies for mono- and co-infected patients; Have an understanding of the treatment challenges in Central/Eastern Europe; Be able to identify and adjust treatment strategies in different patient populations; Have an overview of the advantages and possibilities of new antivirals in HCV therapy. 4

5 MEETING DEMOGRAPHICS NUMBER OF PARTICIPANTS 220 delegates from 33 countries registered for the 3 rd CEE Meeting on Viral Hepatitis and Co-infection with HIV. GEOGRAPHICAL DISTRIBUTION OF REGISTRANTS Slovenia 64 Ukraine 46 Romania 13 Serbia 11 Bulgaria 9 Georgia 9 United Kingdom 8 Croatia 7 Germany 5 Hungary 5 Lithuania 5 Latvia 4 Poland 3 Russia 3 Switzerland 3 Albania 2 Bosnia and Herz. 2 Czech Republic 2 Kazakhstan 2 Moldova 2 Netherlands 2 South Korea 2 Austria 1 Belarus 1 Belgium 1 Israel 1 Kosovo 1 Macedonia 1 Malta 1 Spain 1 Sweden 1 Tajikistan 1 Turkey 1 PERCENTAGE OF RETURNING AND NEW PARTICIPANTS Returning 33% New 67% 5

6 MEETING DEMOGRAPHICS PROFESSIONAL BACKGROUND OF REGISTRANTS Type of organization Occupation University 36% Hospital 48% Medical Doctor 61% NGO 3% Other 8% GO 1% Industry 4% Other 6% Medical Student 11% Researcher 22% Area of expertise Number of patients Other 9% ID 39% Hepatitis 21% Hepatology 14% HIV 17% more than % % % % None 25% % % 6

7 COMMITTEES Charles Boucher, MD, PhD Erasmus MC, Rotterdam, the Netherlands Saulius Caplinskas MD, PhD Lithuanian Centre for Communicable Diseases Andrzej Horban, MD, PhD Hospital for Infectious Diseases, Warsaw, Poland Pavel Khaykin, MD MainFachArzt, Frankfurt, Germany and AIDS, Vilnius, Lithuania Liudmyla Maistat Medicines Patent Pool, Geneva, Switzerland Mojca Maticic, MD, PhD University Medical Centre, Ljubljana, Slovenia Milosz Parczewski, MD, PhD Pomeranian Medical Vadim Rassokhin, MD First St. Petersburg State Medical University named (Co-chair 2017) University, Szczecin, Poland Acad IP Pavlov, Russia Jürgen Rockstroh, MD University of Bonn, Germany (Co-chair 2017) Jonathan Schapiro, MD Sheba Medical Center, Tel Aviv, Israel (Co-chair 2017) Adrian Streinu Cercel, MD, PhD Nat. Institute for Inf. Diseases Prof. Dr. Matei Bals, Bucharest, Romania Cihan Yurdaydin, MD University of Ankara Medical School, Turkey September 2017, Ljubljana, Slovenia 7

8 COMMITTEES LOCAL ORGANIZING COMMITTEE Masa Klesnik, MD University Medical Centre, Ljubljana, Slovenia Mojca Maticic, MD, PhD University Medical Centre, Ljubljana, Slovenia Jerneja Videcnik, MD, PhD University Medical Centre, Ljubljana, Slovenia SCIENTIFIC COMMITTEE Svitlana Antonyak, MD Academy of Medical Sciences, Ukraine Marine Gogia, MD Georgian Harm Reduction Network, Georgia Brygida Knysz, MD, PhD Medical University of Wroclaw, Poland Cristina Popescu, MD, PhD Carol Davila University of Medicine and Pharmacy, Romania Dalibor Sedlácek, MD, PhD University Hospital Plzen, Czech Republic Tengiz Tsertsvadze, MD, PhD I. Javakhishvili Tbilisi State University, Infectious Diseases, AIDS and Clinical Immunology Research Center, Georgia Alicja Wiercinska Drapało, MD, PhD Medical University of Warsaw, Poland September 2017, Ljubljana, Slovenia 8

9 NEEDS ASSESSMENT A seperate needs assessment was conducted on day 1. Feedback was asked on whether participants felt there is a need for a program on viral hepatitis and co-infection with HIV in the CEE region, what they identify as needs / gaps and whether these gaps were met during the workshop. (Strongly) agree Neutral (Strongly) disagree There is a need for a program on hepatitis and co-infection in your region There is a need for a meeting focusing on regional challenges and building collaborations 96% 3% 1% 94% 6% 0% EDUCATIONAL GAPS What educational needs / gaps do you feel the region suffers from the most? Capacity building related needs/gaps 15% Other needs 2% Policy related needs/gaps 19% Access to care related needs/gaps 19% Latest research and development related needs/gaps 23% Clinical management related needs/gaps 22% If other: Predictive diagnosis, preventive programs in the field Financing elimination of Hep C Destigmatiation of the disease To develop multidisciplinary network with HIV in focus To continue such meetings. I would like to future to hear more about studies on the use of drug direct ation on HIV and HCV (HBV) More topics about HBV infection Collaboration with clinical pharmacologists in the region, a small group of people who could be a huge benefit for the region Epidemiology data should be presented including age groups under 18; and above 18 (pediatric patients). The presence of drug company representatives in the round table discussion could make us understand the patent oppostion (Strongly) agree Neutral (Strongly) disagree This year s program has met the need / gap you selected 88% 10% 2% 9

10 PARTICIPANTS FEEDBACK INVITED LECTURES WEDNESDAY, 27 SEPTEMBER Session 1 - Epidemiology / access to treatment Local situation in in Slovenia and Balkan Countries Mojca Maticic, MD, PhD, University of Ljubljana, Slovenia Local situation in Ukraine Olga Golubovska, MD Bogomolets National medical University, Ukraine Topic is interesting 99% 1% 0% 0 Content is relevant to my work 91% 8% 1% 3 Speaker performance 98% 2% 0% 0 Topic is interesting 85% 13% 2% 0 Content is relevant to my work 79% 15% 6% 4 Speaker performance 73% 20% 7% 0 Local situation in Russia Vadim Rassokhin, MD First St. Petersburg State Medical University named Acad IP Pavlov, Russia Local situation in Romania Oana Sandulescu, MD, PhD Carol Davila University of Medicine and Pharmacy, Romania Local situation in Baltic Countries Saulius Caplinskas, MD,PhD Lithuanian Centre for Communicable Diseases and AIDS, Lithuania Local situation in Georgia Akaki Abutidze, MD, MPH AIDS and Clinical Immunology Research Centre, Georgia Topic is interesting 86% 11% 3% 0 Content is relevant to my work 77% 14% 9% 4 Speaker performance 74% 17% 9% 0 Topic is interesting 90% 10% 0% 1 Content is relevant to my work 82% 13% 5% 5 Speaker performance 95% 5% 0% 1 Topic is interesting 89% 11% 0% 0 Content is relevant to my work 82% 14% 4% 4 Speaker performance 88% 10% 2% 0 Topic is interesting 89% 11% 0% 0 Content is relevant to my work 85% 9% 6% 4 Speaker performance 92% 7% 1% 0 10

11 PARTICIPANTS FEEDBACK Local situation in Czech and Slovak Republics Viktor Aster, MD, PhD, Charles University, Czech Republic Local situation in Poland Andrzej Horban, MD, PhD University of Warsaw, Poland Local situation in Hungary Béla Hunyady, MD, PhD Somogy County Kaposi Mór Teaching Hospital, Hungary Hep-CORE study: management of HBV and HCV infections throughout Europe Jeffrey Lazarus, PhD Copenhagen University Hospital, Denmark New testing strategies for HCV: how can we achieve the WHO targets? Mario Poljak, MD, PhD University of Ljubljana, Slovenia Topic is interesting 85% 14% 1% 1 Content is relevant to my work 83% 12% 5% 5 Speaker performance 78% 16% 6% 1 Topic is interesting 80% 18% 2% 0 Content is relevant to my work 76% 20% 4% 4 Speaker performance 63% 28% 9% 0 Topic is interesting 90% 6% 4% 1 Content is relevant to my work 82% 12% 5% 6 Speaker performance 86% 13% 1% 2 Topic is interesting 94% 6% 0% 0 Content is relevant to my work 90% 8% 2% 4 Speaker performance 90% 9% 1% 0 Topic is interesting 95% 5% 0% 0 Content is relevant to my work 94% 6% 0% 3 Speaker performance 95% 4% 1% 0 Round table discussion: access to HepC treatment Topic is interesting 87% 12% 1% 0 Content is relevant to my work 77% 16% 7% 3 Session 2: Challenges in the management of HCV infected patients Management of HCC in HCV -infected patients Markus Peck- Radosavljevic, MD Klinikum Klagenfurt am Wörthersee, Austria Topic is interesting 93% 7% 0% 0 Content is relevant to my work 82% 14% 4% 3 Speaker performance 92% 7% 1% 0 11

12 PARTICIPANTS FEEDBACK Clinical case: re-treatment of HCV DAA failure with 3-class resistance Pavel Khaykin, MD MainFachArzt, Germany Topic is interesting 93% 7% 0% 0 Content is relevant to my work 93% 6% 1% 3 Speaker performance 89% 10% 1% 0 Session 3: Epidemiology, clinical presentation and management of Hepatitis E virus Management of Hepatitis E virus Heiner Wedemeyer, MD Medical School Hannover, Germany Topic is interesting 100% 0% 0% 1 Content is relevant to my work 90% 9% 1% 4 Speaker performance 100% 0% 0% 1 THURSDAY 28 SEPTEMBER Session 4: Treatment challenges in HIV & HCV special populations Special challenges in curbing the HIV epidemic in Central/Eastern Europe Miłosz Parczewski, MD, PhD Pomeranian Medical University, Szczecin, Poland Abstract-driven presentations Results of Hepatitis C virus (hcv) treatment program among people with hiv/hcv co-infection who inject drugs (PWID) Mr. Sergii Filipovich HIV infection outbreak among IDUs in Minsk Prof. Vladimir Eremin Topic is interesting 95% 5% 0% 1 Content is relevant to my work 86% 13% 1% 4 Speaker performance 94% 6% 0% 1 Topic is interesting 82% 14% 4% 2 Content is relevant to my work 72% 22% 6% 6 Topic is interesting 80% 14% 6% 2 Content is relevant to my work 55% 33% 12% 5 12

13 PARTICIPANTS FEEDBACK Session 5: Abstract - driven presentations Real-world effectiveness of ledipasvir/ sofosbuvir in hepatitis C virus genotype 1, 2 and 3 infection: single-center experience within Georgian hepatitis C elimination program Dr. Akaki Abutidze Clinical characteristics of patients seeking care for chronic HCV infection results from the large observational study in Central and Eastern European region and Kazakhstan (MOSAIC Study) Dr. Béla Hunyady Changes in demographic, epidemiological and virological characteristics of patients with chronic hepatitis B virus infection in Slovenia between 1997 and 2010 Dr. Nina Kmet Lunarcek Prognostic factors for liver fibrosis regression following sustained virologic response in patients with hepatitis C treated with direct acting antivirals Dr. Oana Sandulescu Direct-acting antivirals Ombitasvir/ Paritaprevir/Ritonavir + Dasabuvir with or without Ribavirin in HCV genotype 1-infected treatment-naïve or treatment-experienced patients with or without cirrhosis: real-life experience in Lithuania and Latvia Topic is interesting 97% 3% 0% 4 Content is relevant to my work 90% 8% 2% 6 Topic is interesting 91% 6% 3% 4 Content is relevant to my work 86% 11% 3% 6 Topic is interesting 94% 5% 2% 4 Content is relevant to my work 84% 13% 3% 6 Topic is interesting 96% 3% 1% 2 Content is relevant to my work 89% 10% 1% 5 Topic is interesting 89% 10% 2% 3 Content is relevant to my work 86% 12% 2% 5 Dr. Ligita Jancoriene Special session: Future directions of ARVs Virologist Perspective Charles Boucher, MD, PhD, Erasmus University, the Netherlands Topic is interesting 96% 4% 0% 1 Content is relevant to my work 92% 5% 3% 4 Speaker performance 96% 4% 0% 2 13

14 PARTICIPANTS FEEDBACK Clinician Perspective Jonathan Schapiro, MD, Sheba Medical Centre, Israel Pharmacologist Perspective Saye Khoo, MD, PhD, University of Liverpool, United Kingdom Topic is interesting 98% 1% 1% 1 Content is relevant to my work 92% 3% 5% 4 Speaker performance 98% 2% 0% 2 Topic is interesting 95% 5% 0% 1 Content is relevant to my work 92% 5% 3% 4 Speaker performance 93% 5% 2% 2 Session 6: Future in Diagnostic & Therapeutic Approaches Innovative diagnostics for HIV, HBV and HCV Dan Otelea, MD, PhD, Nat. Institute for Inf. Diseases Prof. Dr. Matei Bals, Romania The challenges in hepatitis B vaccination Greet Hendrikx, MD, PhD, University of Antwerpen, Belgium Topic is interesting 93% 5% 2% 2 Content is relevant to my work 89% 7% 4% 4 Speaker performance 93% 5% 2% 2 Topic is interesting 96% 4% 0% 2 Content is relevant to my work 92% 6% 2% 4 Speaker performance 87% 13% 0% 2 POSTER VIEWING SESSION (Strongly) agree Neutral (Strongly disagree N/A The poster viewing session was a valuable addition to the program 85% 5% 0% 5 The poster viewing session was well - timed 98% 2% 0% 5 14

15 PARTICIPANTS FEEDBACK INDUSTRY - SPONSORED SYMPOSIA On the path to elimination: from clinical trials to real world (MSD) Lessons learned from real world experience Heiner Wedemeyer Hannover Medical School, Germany Treating today s populations at risk Martin Kaberg Karolinska University, Sweden Treatment of HCV: the Slovenian example Mojca Maticic University Medical Center, Ljubljana, Slovenia Topic is interesting 99% 1% 0% 4 Content is relevant to my work 94% 6% 0% 5 Topic is interesting 94% 6% 0% 3 Content is relevant to my work 93% 7% 0% 5 Topic is interesting 96% 4% 0% 3 Content is relevant to my work 94% 6% 0% 5 HCV in high risk and HIV co-infected populations : a personal and public health perspective (Abbvie) Overview of HCV infection in high-risk populations Mojca Maticic University Medical Center, Ljubljana, Slovenia Treating today s populations at risk Andrew Ustianowski North Manchester General Hospital, United Kingdom HCV and drug-drug interactions in high risk populations David Back University of Liverpool, UK Topic is interesting 99% 1% 0% 0 Content is relevant to my work 97% 3% 0% 3 Topic is interesting 99% 1% 0% 0 Content is relevant to my work 93% 6% 1% 3 Topic is interesting 99% 1% 0% 0 Content is relevant to my work 97% 3% 0% 2 Going Beyond Together: Evolving HCV Care (Gilead) The need to evolve HCV care Mojca Maticic University Medical Center, Ljubljana, Slovenia Topic is interesting 97% 0% 3% 7 Content is relevant to my work 92% 5% 3% 9 15

16 PARTICIPANTS FEEDBACK Evolving HCV screening and linkage to care Marieta Simonova Military Medical Academy, Bulgaria Evolving HCV treatment Béla Hunyady Somogy County Kaposi Mór Teaching Hospital, Hungary Evolving care through exchange Panel discussion, Q&A Topic is interesting 91% 8% 2% 7 Content is relevant to my work 87% 10% 3% 9 Topic is interesting 92% 5% 3% 7 Content is relevant to my work 89% 8% 3% 8 Topic is interesting 90% 8% 2% 7 Content is relevant to my work 86% 12% 2% 8 16

17 PARTICIPANTS FEEDBACK MEETING OBJECTIVES Educating the practicing clinician on the best treatment options for viral hepatitis & co-infection with HIV.s Sharing state-of-the-art information and how it relates to daily clinical practice.e Providing a Central/Eastern European platform for interaction and dialogue. 97% 2% 1% 0 97% 3% 0% 0 98% 2% 0% 0 Stimulating discussion among different disciplines. 93% 7% 0% 0 Building collaborations and developing research activities 91% 7% 2% 1 LEARNING OBJECTIVES After attending this meeting, the participants will: Have an understanding of the basic concepts of viral hepatitis and HIV coinfection. Have an insight into the spread of viral hepatitis and HIV in Central/Eastern Europe. Be updated on the latest developments in treatment strategies for hepatitis mono-and HIV co-infected patients Have an understanding of the specific treatment challenges in Central/Eastern Europe. Be able to identify and adjust treatment strategies in different patient populations. Have an overview of the advantages and possibilities of new antivirals in HCV and HIV therapy. 97% 3% 0% 0 98% 2% 0% 0 98% 2% 0% 0 98% 2% 0% 0 95% 2% 3% 0 97% 2% 1% 0 CONFERENCE ORGANIZATION Excellent / good Average Fair / poor N/A Content of electronic announcements (VE newsletters) 97% 3% 0% 1 Frequency of electronic announcements (VE newsletters) 96% 4% 0% 1 Information on the conference website 95% 5% 0% 0 Online registration process 95% 4% 1% 2 Online abstract submission process 100% 0% 0% 14 Meeting venue 99% 1% 0% 0 Meeting room 99% 1% 0% 0 Audiovisuals 96% 4% 0% 0 Food & Beverage 99% 1% 0% 0 Onsite logistics 99% 1% 0% 2 Service level of Conference Secretariat 100% 0% 0% 2 17

18 PARTICIPANTS FEEDBACK GENERAL CONFERENCE EXPERIENCE Excellent / good Average Fair / poor N/A Overall event experience 97% 3% 0% 0 Opportunity of networking 98% 0% 2% 2 Time allocation for discussion 90% 10% 0% 0 Time allocation per presentation 98% 2% 0% 0 No commercial bias (product selling) perceived 90% 5% 5% 0 I would recommend this conference to my peers 97% 2% 1% 1 Plan to attend this conference next year 85% 15% 0% 1 INTENT TO CHANGE The lectures given in this workshop have increased my knowledge on Viral hepatitis and co-infection with HIV in de CEE countries This program is beneficial for the clinical management of my patients I intend to incorporate the new information into the care of my patients 97% 3% 0% 0 95% 5% 0% 9 98% 0% 2% 9 I will be able to implement without any problems 38% I intend to apply the gained knowledge, but some of the following factors may prevent the implementation (multiple answerswerepossible): My patient population may not be appropriate for the implementation 13% My current office and practice systems may not accommodate the changes 25% My patients may have trouble complying with these changes/ strategies 3% The medications/ procedures discussed may not be available for my patients 44% These changes may be too time consuming 16% 18

19 MEETING METRICS My attention to this meeting was drawn by; Multiple answers were allowed. VE Website/ Newsletter Referred by colleague/ word-of-mouth Invite from the faculty members Invite from the Industry Announcement through partner societies Flyer at other VE meetings Flyer at non-ve meetings other I was motivated to attend this meeting by: Multiple answers were allowed. Scientific program Meeting objectives Faculty / speakers Meeting location Experience from previous meetings Faculty / speakers Free registration / grantee Free registration / industry Free registration / YI CME credits

20 CONCLUSION The Organizing Secretariat is pleased with the results of the 3 TH CENTRAL AND EASTERN EUROPEAN MEETING ON VIRAL HEPATITIS AND CO-INFECTION WITH HIV. Most of the participants were impressed by the quality of the scientific content and the time allocation for the discussions. The majority also reported that they were satisfied with the overall meeting logistical arrangements and agreed it was a well-organized event. Both the evaluation results and the participants feedback proved the success and the importance of this conference. The needs assessment, conducted on Day 1 (p. 9) shows that 95% of the participants feel the need programs on viral hepatitis and co-infection with HIV, focused on regional challenges and building collaborations. Therefore, the Organizing Secretariat will invite the Organizing Committee to further discuss the preparation and the development of the scientific program for next year's edition, planned for October 2018 in Prague, Czech Republic. 20

21 ACKNOWLEDGEMENTS SPONSORS PLATINUM LEVEL GOLD LEVEL SUPPORTER MEETING PARTNERS THE MEETING IS HELD UNDER THE AUSPICES OF THE MEETING IS ENDORSED BY 21

22